Literature DB >> 6467175

Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.

A Abuchowski, G M Kazo, C R Verhoest, T Van Es, D Kafkewitz, M L Nucci, A T Viau, F F Davis.   

Abstract

The covalent attachment of monomethoxypolyethylene glycol (PEG) to asparaginases from Escherichia coli and Vibrio succinogenes by new coupling methodology produced conjugates that are active, stable, without significant immune response, and with greatly extended plasma half-lives in mice. Therapeutic efficacies were greater for the PEG-asparaginases than for the unmodified asparaginases in mice infected with the L5178Y lymphosarcoma or the 6C3HED tumor. Large single doses of native or modified enzymes were more effective against tumors than the same amount of enzyme given in smaller doses over several days.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467175

Source DB:  PubMed          Journal:  Cancer Biochem Biophys        ISSN: 0305-7232


  37 in total

1.  Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

Authors:  Joanne Kurtzberg; Barbara Asselin; Mark Bernstein; George R Buchanan; Brad H Pollock; Bruce M Camitta
Journal:  J Pediatr Hematol Oncol       Date:  2011-12       Impact factor: 1.289

2.  Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.

Authors:  Dana L Long; Daniel H Doherty; Stephen P Eisenberg; Darin J Smith; Mary S Rosendahl; Kurt R Christensen; Dean P Edwards; Elizabeth A Chlipala; George N Cox
Journal:  Exp Hematol       Date:  2006-06       Impact factor: 3.084

3.  Degradable PEGylated Protein Conjugates Utilizing RAFT Polymerization.

Authors:  Caitlin G Decker; Heather D Maynard
Journal:  Eur Polym J       Date:  2015-04-01       Impact factor: 4.598

4.  Site-Specific Protein PEGylation: Application to Cysteine Analogs of Recombinant Human Granulocyte Colony-Stimulating Factor.

Authors:  Mary S Rosendahl; Daniel H Doherty; Darin J Smith; Alison M Bendele; George N Cox
Journal:  Bioprocess Int       Date:  2005-04

5.  Targeting of skeletal muscle in vitro using biotinylated immunoliposomes.

Authors:  Anita Schnyder; Stefan Krähenbühl; Michael Török; Jürgen Drewe; Jörg Huwyler
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

6.  Fingerprinting proteins coupled with polymers by mass spectrometry: Investigation of polyethylene glycol-conjugated superoxide dismutase.

Authors:  S K Chowdhury; M Doleman; D Johnston
Journal:  J Am Soc Mass Spectrom       Date:  1995-06       Impact factor: 3.109

7.  Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.

Authors:  S L Berg; F M Balis; C L McCully; K S Godwin; D G Poplack
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations.

Authors:  Beata Zalewska-Szewczyk; Agnieszka Gach; Krystyna Wyka; Jerzy Bodalski; Wojciech Młynarski
Journal:  Clin Exp Med       Date:  2009-01-30       Impact factor: 3.984

Review 9.  Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.

Authors:  Melike Uner; Gülgün Yener
Journal:  Int J Nanomedicine       Date:  2007

10.  First-line treatment of acute lymphoblastic leukemia with pegasparaginase.

Authors:  Riccardo Masetti; Andrea Pession
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.